Our vision is to impact patient lives by providing an optimal platform for the innovation of the next generation of imaging agents, which will improve diagnostic and therapeutic care, leading to better clinical outcomes.
C11-Choline is a radioactive diagnostic agent for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging. In these patients, C11-Choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy. In clinical studies, images were produced with PET/CT coregistration. Limitation of Use: C11-Choline PET imaging is not a replacement for histologic verification of recurrent prostate cancer.
F18-Fludeoxyglucose (18F-FDG) is indicated for positron emission tomography (PET) imaging in the following settings:
Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.
Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.
Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.
N13-Ammonia is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
F18-Sodium Fluoride is a radioactive diagnostic agent for positron emission tomography (PET) indicated for imaging of bone to define areas of altered osteogenic activity.
Advancing Imaging to Improve Patient Care and Outcomes
2018 Online Learning Series
Just announced! Part 1 of the 2018 Online Learning Series, including the latest information on research trends in nuclear medicine. Be sure to register and join these informative sessions focused on the evidence-based utilization of advanced imaging to improve patient care. A select number of the Online Learning Series webinars have been accredited through recognized programs for technologists to receive CEH.
2018 Webinar Series Part 2 – (Click here to download schedule)
Upcoming Webinar: Utilizing PET/CT for Liquid Tumors
Jan. 31, 2018 3pm EST
In this sessions, Robert S. Bridwell, MD, MBA, noted PET physician and educator, will outline the utilization of FDG PET/CT in lymphoma and other “liquid” tumors. He will review its role in staging, response assessment, prognosis after completion of therapy, restaging and surveillance. The increased utilization of ‘interim’ or early PET restaging is also discussed, as well as its specific application in particular forms of lymphoma. Limitations of the modality are detailed, including the notation of subtypes where PET may be conducive to false negatives.
Looking for more education on PET Imaging?
Just go to PETLinQ IQ, SOFIE’s PET education web portal, where you can find pertinent scientific articles, case studies, referrer guides, sample flowcharts and additional presentations, all updated on a regular basis. The IQ Learning Center offers online courses eligible for technologist CE credit. Visit www.petlinqiq.com and sign up today!
ResearchPioneering the Next Generation of Imaging Agents
SOFIE is committed to the future of molecular imaging and the development of a new generation of disease-specific tracers and companion therapeutics. Our efforts are focused in two key areas. First, we are working with pharmaceutical, biotech and academic medical community partners in the development of new, targeted molecular tracers employing high resolution PET/CT technology and designed to provide accurate, specific diagnostic information for physicians. Development of these radiopharmaceuticals is expected to significantly broaden the impact of molecular medicine. Areas of research include kidney cancer, apoptosis, Alzheimer’s Disease, hypoxia, Parkinson’s, angiogenesis, cardiac perfusion, Dementia with Lewy bodies, acute coronary syndrome and a range of specific cancer indications.
Second, SOFIE is providing pharmaceutical firms, biotech companies and research institutions with a full range of radiopharmaceutical development services for diagnostic and therapeutic compounds. The company’s Centers of Innovation, along with the SOFIE network of pharmacies, offer expertise in radiolabelling, “scale-up” to manufacturing, technology transfer and production of doses for clinical trials. SOFIE relies on its proven expertise of developing, registering and supplying radiopharmaceuticals under strict CGMP standards. Our goal is to help accelerate the development of new products to positively impact patient care and outcomes.
For more information about our research products, please email us at firstname.lastname@example.org